SLIDE 48
- T32 DK07727, Program Director: MB Cohen, Training Program in Pediatric
Gastroenterology and Nutrition: 5% effort; 07/01/05 - 06/30/15 $2,009,290
- DK058701 Studies on intestine-enriched transcription factor, IKLF (20% effort) 09/01/2001
- 06/30/2006, MB Cohen, PI
- Regulation of gastrointestinal eosinophils (NIH: DK 45898-01), (P.I.: M. Rothenberg, MD,
Ph.D.) 09/01/99 - 08/30/04 $1,095,267, Co-investigator, 5% effort, 09/01/99 - 08/30/00 $207,366
- R24 DK 064403, Cincinnati DDRDC: Center for Growth and Development (CGD),
04/01/03-03/31/08, MB Cohen, PI (15% effort)
- NIH:P30 DK 0789392 07/01/07-05/31/12 Role: Program Director (7/1/07-5/31/09),
Associate Director 6/1/09-05/31/12) Digestive Health Center: Bench to Bedside Research in Pediatric Digestive Disease
- NIH: Test kit to quantify fat absorption in cystic fibrosis. (R42 DK 48537), (M.
Janghorbani, PI), $388,817; Co-investigator, 15% effort, 11/01/96-10/30/98 (subcontract $120,503)
- NIH: Biomedical Research Support Grant (RR 05535) Enteroaggregative Escherichia coli
heat stable toxin, May 1991 - March 1992, $11,000
- NIH: Biomedical Research Support Grant (RR 05535): Localization of guanylin and the E.
coli heat stable enterotoxin receptor by in situ hybridization, December 1992 - September 1993, $7,500.
- NIH: Test kits for measuring malabsorption in cystic fibrosis. (R41 DK 48537), (M.
Janghorbani, PI), 5% effort, $100,000, subcontract, 9/30/94-9/29/95, $30,350.
- NIH: Development of accurate test kits for malabsorption. (R43 DK 48190), (M.
Janghorbani, PI), 7% effort, $79,324, subcontract, 9/30/94-3/31/95, $10,000.
- Borderline pancreatic function in cystic fibrosis. (R43DK55924-01A1), (M. Janghorbani, PI),
$91,415; Co-investigator, 5% effort, 06/01/00-05/31/01 (subcontract $30,000)
- NIAID-DMID-94-29: N01-A145252: Evaluation of control measures against human
infectious diseases other than AIDS. Co-investigator. (GM Schiff, PI.), MB Cohen Coinvestigator: 25% effort, 1994-2002, $11,374,000
- DMID Protocol # 07-0052 A Randomized, Double-blind, Placebo-controlled Dose
Escalation, Inpatient Phase I Study to Determine the Safety and Immunogenicity of a Single Oral Dose of a Combined Enterotoxigenic E. Coli (ETEC)-Cholera Vaccine (Peru 15 pCTB) in Healthy Adult Subjects, 30% effort, 11/1/07-5/30/10
- NIH: NIAID-DMID-N01-AI-25459: Evaluation of control measures against human
infectious diseases other than AIDS. Co-investigator. (David Bernstein, PI.), MB Cohen PI
- f Enteric Vaccine: 30% effort, 6/1/02-5/31/07; 10% effort 11/1/07-10/31/12.
- DMID Protocol 09-0066; Phase I Study to Determine the Safety and Efficacy of an Oral
ETEC Candidate Vaccine, Attenuated, Recombinant Double Mutant Heat- Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli, 20% effort
Non-NIH funding
- American Gastroenterological Association
– Supplemental Research Training Award, July 1985- June 1986, $7,500 – Industry (Glaxo) Scholar Award, "Regulation of ST-induced intestinal secretion," July 1988- June 1991, $75,000 – Research Preceptorship, Michelle R. Ritter, Summer Student, May 1989- August 1989, $1,500 – Mentor, AGA Senior Fellowship Research Award to Dr. Glen Lewis, July 1993-June 1994, $7,500. – AGA Summer Undergraduate Research Fellowship to Noeet Elitsur, ($4000), 2003 – Sponsor/Mentor: Praveen Goday 1999-2001 ($72,000) – Sponsor/Mentor: Jeffrey Rudolph, MD 2000-2002 ($72,000)
– Mentor, American Liver Foundation Award to Dr. Jane Balint, July 1994-June 1995, $7,500.
– Unrestricted Educational Grant 1999, $3,995
– Choleragard planning grant, MB Cohen PI $10,000 07/01/06-06/30/07
– "Intestinal receptor for E. coli heat-stable enterotoxin: Increased receptor density and potential role as a receptor for an intestinally active growth factor in perinatal life," July 1989- June 1990, $9,000. – Principal Investigator: Safety and Efficacy of Rice Based Oral Rehydration Solution. January 1990- March 1993, $111,120
– Regulation of STa-induced intestinal secretion.“ Trustee Award, July 1988-June 1991, $92,000 – Translational Research Initiative, $3,000 DDRC Retreat, 2002
- Cystic Fibrosis Foundation
– Expression and function of the guanylin ligand family (P978), July 1, 1995-July 1, 1996. $32,493. – First Year Clinical Fellowship Sponsor (Jeffrey Rudolph), (Rudolp97B0), 1997-98 ($30,500) – Fellowship Sponsor (Stephen Guthery), (GUTHER99B0), 1999-01 ($76,000) – Fellowship Sponsor (Valerie McLin (MCLIN01B0) 2001-3 ($84,500) – Clinical Fellowship to Nissa Erickson (ERICKS03B0)July 1, 2003-June 30, 2004 $42,000 – First Year Fellowship Award (Pasternak PASTER05B0) 7/1/05-6/30/06) 7/1/05-6/30/06 $42,000
- Marion Merrell Dow Foundation
– Transgenic models of cardiovascular disease: Guanylin overexpression in transgenic mice, 1994, $2,000 – Transgenic models of cardiovascular disease: Targeting of the guanylin gene, 1996 ($4600) – Transgenic models of cardiovascular disease: Targeting of the uroguanylin gene, 1997 ($4600)
- Mead Johnson Nutritional Group
– Development of accurate test kits for malabsorption. Project 8538. September 1994-September 1995. $24,000
- Miles Pharmaceutical Company:
– Prospective, controlled double blind randomized comparison of ciprofloxacin vs trimethoprim/sulfamethoxazole vs placebo for prevention of traveler's diarrhea. Jeff Heck, Principal Investigator; Responsible for Component III:Escherichia coli pathogen assays, February 1990- May 1992, 5% effort, $79,100 – Prospective, double-blind, randomized comparison of Ciprofloxacin 500 mg daily for 3 days vs. trimethoprim- sulfamethoxazole 160/800mg twice daily for 5 days for the empiric therapy of traveler's diarrhea. (Jeff Heck, Principal Investigator), Responsible for Component III, Escherichia coli pathogen assays, October 1992- April, 1993, 5% effort, $26,259.
- Procter and Gamble Company
– Escherichia coli pathogen assays. February 1993-February 1994. $80,000. – Efficacy of bismuth subsalicylate in decreasing stool output in children with short bowel syndrome or intestinal
- aganglionosis. September 1994- September 1995, $25,000
– Fellowship Research and Education, 1997-1998, $5,000 – Unrestricted Educational Grant, 1998, $2,400 – Bifido 624 in Prevention of Day Care Diarrhea, MB Cohen, PI 06/15/02-10/15/03 $367,000